Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus TEXACORT.
FLUDROCORTISONE ACETATE vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
0.1 mg orally once daily, range 0.05-0.2 mg/day
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category D/X
Category C
Corticosteroid
Corticosteroid